Insider trade

Director sold ~$24K of UTHR shares in the open market

Traded Feb 17, 2026 · Filed Feb 18, 2026

Why it stands out

A United Therapeutics director sold $24K of United Therapeutics shares. The filing says it was made under a pre-arranged trading plan.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Director<$25KPre-arranged plan referenced

Classification

open market sale

Code S — open-market or private sale

Absolute commitment

~$23,734

Shares × reported transaction price

Timing vs results

111 days after results of Oct 29, 2025, 8 days before results of Feb 25, 2026

Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results

Planned / mechanical clue

Footnote references a pre-arranged trading plan (Rule 10b5-1)

Only flagged when a footnote says so; never inferred

After	Stock	S&P 500	Difference
7 days	+12.4%	+1.0%	+11.4%
30 days	+10.1%	−5.5%	+15.6%
90 days	+19.1%	+6.9%	+12.2%
180 days	+6.8%	+12.6%	−5.8%

Past results only. Not a forecast.

This sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on September 11, 2025.

Filed 7mo ago

Traded Mar 18 · filed 2 days later

Derivative exercise or conversion — not an open-market buy.

Scheduled in advanceFiled 7mo ago

Scheduled in advanceFiled 7mo ago